Enanta Pharmaceuticals’ (ENTA) Market Outperform Rating Reiterated at JMP Securities

JMP Securities reiterated their market outperform rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a report released on Tuesday,Benzinga reports. They currently have a $21.00 target price on the biotechnology company’s stock, down from their prior target price of $22.00.

ENTA has been the subject of a number of other research reports. Evercore ISI raised Enanta Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of Enanta Pharmaceuticals in a research note on Thursday, October 10th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating on the stock in a research report on Tuesday, August 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $19.50.

Enanta Pharmaceuticals Stock Up 3.2 %

Shares of NASDAQ:ENTA opened at $8.83 on Tuesday. The firm has a fifty day moving average of $10.87 and a two-hundred day moving average of $12.28. Enanta Pharmaceuticals has a 12-month low of $8.00 and a 12-month high of $17.80. The firm has a market capitalization of $187.11 million, a P/E ratio of -1.61 and a beta of 0.56.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ENTA. Farallon Capital Management LLC raised its position in shares of Enanta Pharmaceuticals by 3.5% in the first quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock valued at $36,579,000 after purchasing an additional 70,000 shares during the period. Vanguard Group Inc. grew its stake in Enanta Pharmaceuticals by 7.5% in the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock valued at $33,664,000 after buying an additional 134,292 shares during the last quarter. Krensavage Asset Management LLC raised its holdings in Enanta Pharmaceuticals by 19.7% in the 3rd quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock worth $15,520,000 after acquiring an additional 246,736 shares during the period. Geode Capital Management LLC lifted its position in Enanta Pharmaceuticals by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock worth $4,946,000 after acquiring an additional 14,575 shares during the last quarter. Finally, State Street Corp lifted its position in Enanta Pharmaceuticals by 6.4% during the 3rd quarter. State Street Corp now owns 449,975 shares of the biotechnology company’s stock worth $4,662,000 after acquiring an additional 27,147 shares during the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.